Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.

Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI

Open source

DOI: 10.1038/s41698-021-00232-w
Published: 2021 Oct 19
Container: NPJ precision oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41698-021-00232-w,
  title = {Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.},
  author = {Labrie M and Li A and Creason A and Betts C and Keck J and Johnson B and Sivagnanam S and Boniface C and Ma H and Blucher A and Chang YH and Chin K and Vuky J and Guimaraes AR and Downey M and Lim JY and Gao L and Siex K and Parmar S and Kolodzie A and Spellman PT and Goecks J and Coussens LM and Corless CL and Bergan R and Gray JW and Mills GB and Mitri ZI},
  year = {2021},
  journal = {NPJ precision oncology},
  doi = {10.1038/s41698-021-00232-w},
  url = {https://doi.org/10.1038/s41698-021-00232-w}
}

RIS

TY  - JOUR
TI  - Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.
AU  - Labrie M
AU  - Li A
AU  - Creason A
AU  - Betts C
AU  - Keck J
AU  - Johnson B
AU  - Sivagnanam S
AU  - Boniface C
AU  - Ma H
AU  - Blucher A
AU  - Chang YH
AU  - Chin K
AU  - Vuky J
AU  - Guimaraes AR
AU  - Downey M
AU  - Lim JY
AU  - Gao L
AU  - Siex K
AU  - Parmar S
AU  - Kolodzie A
AU  - Spellman PT
AU  - Goecks J
AU  - Coussens LM
AU  - Corless CL
AU  - Bergan R
AU  - Gray JW
AU  - Mills GB
AU  - Mitri ZI
PY  - 2021
JO  - NPJ precision oncology
DO  - 10.1038/s41698-021-00232-w
UR  - https://doi.org/10.1038/s41698-021-00232-w
ER  -

APA

M, L., A, L., A, C., C, B., J, K., B, J., S, S., C, B., H, M., A, B., YH, C., K, C., J, V., AR, G., M, D., JY, L., L, G., K, S., S, P., A, K., PT, S., J, G., LM, C., CL, C., R, B., JW, G., GB, M., & ZI, M. (2021). Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.. NPJ precision oncology. https://doi.org/10.1038/s41698-021-00232-w

Source records

pubmed · retrieved 2026-09-27T00:05:02.130Z